Undervalued Biotech's

Description:

With the merger between Pfizer (PFE) and Wyeth (WYE), the attempted takeover of Genentech (DNA) by Roche, and the overall positive action in Amgen (AMGN), Celgene Corp (CELG), Genzyme (GENZ), and Geilead (GILD) recently, many analysts and investors believe that 2009 will be a positive year for the biotech industry as a whole.
Important events in the biotech space include Dendreon’s (DNDN) binary data announcement on its key drug Provenge in early April and Genentech’s (DNA) update on various uses for Avastin late April.

Most Viewed Portfolios

View All

Articles

7 Stocks Shoveling More Cash to Investors

06.01.12 | 07:19 AM

  BALTIMORE (Stockpickr) -- To heck with the “summer doldrums.” Believe it or not, plenty of companies are trying to shovel more cash to i...

4 Loser Stocks Poised for Big Rebounds

06.01.12 | 07:18 AM

NEW YORK (Stockpickr) -- Just two months ago, investors had plenty of reason to cheer. The stock market was half a year in to a solid rally that be...

More Articles
blog comments powered by Disqus
Get started with stockpickr! Get recommendations from thousands of mutual funds, hedge funds, and others. Enter your favorite stocks now!
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter